View Item 

Show simple item record

Breast cancer patients’ insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial
dc.contributor.authorSadigh, Gelareh
dc.contributor.authorGray, Robert J.
dc.contributor.authorSparano, Joseph A.
dc.contributor.authorYanez, Betina
dc.contributor.authorGarcia, Sofia F.
dc.contributor.authorTimsina, Lava R.
dc.contributor.authorSledge, George W.
dc.contributor.authorCella, David
dc.contributor.authorWagner, Lynne I.
dc.contributor.authorCarlos, Ruth C.
dc.date.accessioned2021-07-01T20:12:25Z
dc.date.available2022-08-01 16:12:24en
dc.date.available2021-07-01T20:12:25Z
dc.date.issued2021-07-15
dc.identifier.citationSadigh, Gelareh; Gray, Robert J.; Sparano, Joseph A.; Yanez, Betina; Garcia, Sofia F.; Timsina, Lava R.; Sledge, George W.; Cella, David; Wagner, Lynne I.; Carlos, Ruth C. (2021). "Breast cancer patients’ insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial." Cancer (14): 2545-2552.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/168322
dc.publisherAmerican Cancer Society
dc.publisherWiley Periodicals, Inc.
dc.subject.otheradherence
dc.subject.otherbreast cancer
dc.subject.otherendocrine therapy
dc.subject.otherinsurance
dc.subject.othersocial determinants of health
dc.titleBreast cancer patients’ insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168322/1/cncr33527_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168322/2/cncr33527.pdf
dc.identifier.doi10.1002/cncr.33527
dc.identifier.sourceCancer
dc.identifier.citedreferenceChapter 3: creation of new race‐ethnicity codes and SES indicators for Medicare beneficiaries—Chapter 3. January 2008. Agency for Healthcare Research and Quality. Accessed March 12, 2021. http://archive.ahrq.gov/research/findings/final‐reports/medicareindicators/medicareindicators3.html
dc.identifier.citedreferenceShort LJ, Fisher MD, Wahl PM, et al. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Cancer. 2010; 116: 193 ‐ 202.
dc.identifier.citedreferencePrehn AW, Topol B, Stewart S, Glaser SL, O’Connor L, West DW. Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women. Cancer. 2002; 95: 2268 ‐ 2275.
dc.identifier.citedreferenceWu XC, Lund MJ, Kimmick GG, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline‐concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2012; 30: 142 ‐ 150.
dc.identifier.citedreferenceGotay C, Dunn J. Adherence to long‐term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2011; 11: 709 ‐ 715.
dc.identifier.citedreferenceKimmick GG, Li X, Fleming ST, et al. Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. J Geriatr Oncol. 2018; 9: 214 ‐ 220.
dc.identifier.citedreferenceWagner VL, Jing W, Boscoe FP, Schymura MJ, Roohan PJ, Gesten FC. Improving adjuvant hormone therapy use in Medicaid managed care–insured women, New York State, 2012‐2014. Prev Chronic Dis. 2016; 13: E120.
dc.identifier.citedreferenceWheeler SB, Kohler RE, Reeder‐Hayes KE, et al. Endocrine therapy initiation among Medicaid‐insured breast cancer survivors with hormone receptor–positive tumors. J Cancer Surviv. 2014; 8: 603 ‐ 610.
dc.identifier.citedreferenceArtiga S, Hinton E. Beyond health care: the role of social determinants in promoting health and health equity. Kaiser Family Foundation. May 10, 2018. Accessed March 12, 2021. https://www.kff.org/racial‐equity‐and‐health‐policy/issue‐brief/beyond‐health‐care‐the‐role‐of‐social‐determinants‐in‐promoting‐health‐and‐health‐equity/
dc.identifier.citedreferenceHershman DL, Tsui J, Meyer J, et al. The change from brand‐name to generic aromatase inhibitors and hormone therapy adherence for early‐stage breast cancer. J Natl Cancer Inst. 2014; 106: dju319.
dc.identifier.citedreferenceSparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21‐gene expression assay in breast cancer. N Engl J Med. 2015; 373: 2005 ‐ 2014.
dc.identifier.citedreferenceSparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019; 380: 2395 ‐ 2405.
dc.identifier.citedreferenceYung RL, Hassett MJ, Chen K, et al. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012; 104: 1102 ‐ 1105.
dc.identifier.citedreferenceBhavsar NA, Gao A, Phelan M, Pagidipati NJ, Goldstein BA. Value of neighborhood socioeconomic status in predicting risk of outcomes in studies that use electronic health record data. JAMA Netw Open. 2018; 1: e182716.
dc.identifier.citedreferenceBerkowitz SA, Traore CY, Singer DE, Atlas SJ. Evaluating area‐based socioeconomic status indicators for monitoring disparities within health care systems: results from a primary care network. Health Serv Res. 2015; 50: 398 ‐ 417.
dc.identifier.citedreferenceArea Health Resources Files. Health Resources and Services Administration. Accessed June 19, 2020. https://data.hrsa.gov/topics/health‐workforce/ahrf
dc.identifier.citedreferenceHuiart L, Ferdynus C, Giorgi R. A meta‐regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat. 2013; 138: 325 ‐ 328.
dc.identifier.citedreferenceStephen P. The cost of tamoxifen vs. aromatase inhibitors. Verywell Health. Accessed May 8, 2020. https://www.verywellhealth.com/compared‐cost‐effectiveness‐of‐tamoxifen‐and‐arimidex‐430669
dc.identifier.citedreferenceObeng‐Gyasi S, Kircher SM, Lipking KP, et al. Oncology clinical trials and insurance coverage: an update in a tenuous insurance landscape. Cancer. 2019; 125: 3488 ‐ 3493.
dc.identifier.citedreferenceLivaudais JC, Li C, John EM, et al. Racial and ethnic differences in adjuvant hormonal therapy use. J Womens Health (Larchmt). 2012; 21: 950 ‐ 958.
dc.identifier.citedreferenceMode NA, Evans MK, Zonderman AB. Race, neighborhood economic status, income inequality and mortality. PLoS One. 2016; 11: e0154535.
dc.identifier.citedreferenceAlbain KS, Gray RJ, Makower DF, et al. Race, ethnicity and clinical outcomes in hormone receptor–positive, HER2‐negative, node‐negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. Published online September 28, 2020. doi: 10.1093/jnci/djaa148
dc.identifier.citedreferencePrescription drug trends. Kaiser Family Foundation; 2010. Accessed March 12, 2021. https://www.kff.org/wp‐content/uploads/2013/01/3057‐08.pdf
dc.identifier.citedreferenceSadigh G, Gallagher K, Obenchain J, et al. Pilot feasibility study of an oncology financial navigation program in brain cancer patients. J Am Coll Radiol. 2019; 16: 1420 ‐ 1424.
dc.identifier.citedreferenceSadigh G, Carlos RC, Krupinski EA, Meltzer CC, Duszak R Jr. Health care price transparency and communication: implications for radiologists and patients in an era of expanding shared decision making. AJR Am J Roentgenol. 2017; 209: 959 ‐ 964.
dc.identifier.citedreferenceSherman DE. Transforming practices through the oncology care model: financial toxicity and counseling. J Oncol Pract. 2017; 13: 519 ‐ 522.
dc.identifier.citedreferenceChin AL, Bentley JP, Pollom EL. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer. 2019; 125: 374 ‐ 381.
dc.identifier.citedreferenceCarlos RC, Lowry KP, Sadigh G. The coronavirus disease 2019 (COVID‐19) pandemic: a patient‐centered model of systemic shock and cancer care adherence. J Am Coll Radiol. 2020; 17: 927 ‐ 930.
dc.identifier.citedreferenceBurns ME, Huskamp HA, Smith JC, Madden JM, Soumerai SB. The effects of the transition from Medicaid to Medicare on health care use for adults with mental illness. Med Care. 2016; 54: 868 ‐ 877.
dc.identifier.citedreferenceSchumacher JR, Smith MA, Liou JI, Pandhi N. Insurance disruption due to spousal Medicare transitions: implications for access to care and health care utilization for women approaching age 65. Health Serv Res. 2009; 44: 946 ‐ 964.
dc.identifier.citedreferenceLiu B, Lee FF, Boscoe F. Residential mobility among adult cancer survivors in the United States. BMC Public Health. 2020; 20: 1601. doi: 10.1186/s12889‐020‐09686‐2
dc.identifier.citedreferenceAmerican Cancer Society. Cancer Facts & Figures 2019. American Cancer Society; 2019.
dc.identifier.citedreferenceBurstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010; 28: 3784 ‐ 3796.
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687 ‐ 1717.
dc.identifier.citedreferenceDavies C, Godwin J, Gray R, et al; Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient‐level meta‐analysis of randomised trials. Lancet. 2011; 378: 771 ‐ 784.
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient‐level meta‐analysis of the randomised trials. Lancet. 2015; 386: 1341 ‐ 1352.
dc.identifier.citedreferenceSparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21‐gene expression assay in breast cancer. N Engl J Med. 2018; 379: 111 ‐ 121.
dc.identifier.citedreferenceRuddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59: 56 ‐ 66.
dc.identifier.citedreferenceBarron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007; 109: 832 ‐ 839.
dc.identifier.citedreferenceMiaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs. 2008; 12: 213 ‐ 221.
dc.identifier.citedreferenceMa AM, Barone J, Wallis AE, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg. 2008; 196: 500 ‐ 504.
dc.identifier.citedreferenceDemissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001; 19: 322 ‐ 328.
dc.identifier.citedreferenceSimon R, Latreille J, Matte C, Desjardins P, Bergeron E. Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow‐up. Can J Surg. 2014; 57: 26 ‐ 32.
dc.identifier.citedreferenceFyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 963 ‐ 970.
dc.identifier.citedreferenceFisher B, Anderson S, Tan‐Chiu E, et al. Tamoxifen and chemotherapy for axillary node–negative, estrogen receptor–negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B‐23. J Clin Oncol. 2001; 19: 931 ‐ 942.
dc.identifier.citedreferenceHershman D, Moseley A, Arnold KB, et al. Predictive model of aromatase inhibitor non‐adherence using patient‐reported outcomes in women with breast cancer (SWOG S1105). J Clin Oncol. 2020; 38 ( suppl ): 12019.
dc.identifier.citedreferenceChlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006; 71: 1 ‐ 9.
dc.identifier.citedreferenceHutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high‐risk, node‐negative breast cancer: treatment results of Intergroup Protocol INT‐0102. J Clin Oncol. 2005; 23: 8313 ‐ 8321.
dc.identifier.citedreferenceMurphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134: 459 ‐ 478.
dc.identifier.citedreferenceChlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila). 2014; 7: 378 ‐ 387.
dc.identifier.citedreferenceNeugut AI, Subar M, Wilde ET, et al. Association between prescription co‐payment amount and compliance with adjuvant hormonal therapy in women with early‐stage breast cancer. J Clin Oncol. 2011; 29: 2534 ‐ 2542.
dc.identifier.citedreferenceHershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early‐stage breast cancer patients. J Clin Oncol. 2010; 28: 4120 ‐ 4128.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33527_am.pdf
Size:
276.3KB
Format:
PDF
View/Open
Name:
cncr33527.pdf
Size:
192.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.